Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Racemethionine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 10/20 | 0.40 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | GSR | P00390 | 2/20 | 0.33 |
| ▸ | GRM8 | O00222 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methionine SCHEMBL692981 | 1.00 | BHMT (0.40) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Methionine SCHEMBL5582474 | 1.00 | BHMT (0.40) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Methionine SCHEMBL6361609 | 0.97 | BHMT (0.42) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL6361604 | 0.97 | BHMT (0.42) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL3995865 | 0.95 | BHMT (0.43) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Methionine SCHEMBL3995878 | 0.95 | BHMT (0.43) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL4361129 | 0.92 | BHMT (0.46) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Methionine SCHEMBL4361132 | 0.92 | BHMT (0.46) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL7953819 | 0.92 | BHMT (0.45) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL27729867 | 0.92 | BHMT (0.45) | BHMTBHMT2RNPEPNOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024074847-A1 | COMPOSITIONS FOR DETECTING BIOLOGICAL AGENTS | PATH SPRAY LTD (GB) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024069175-A1 | CLOSTRIDIAL NEUROTOXINS COMPRISING AN ACTIVATING ENDOSOMAL PROTEASE CLEAVAGE SITE | IPSEN BIOPHARM LIMITED (GB) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024069191-A1 | CLOSTRIDIAL NEUROTOXIN FOR USE IN A TREATMENT OF BLADDER PAIN SYNDROME | IPSEN BIOPHARM LIMITED (GB) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024069176-A1 | CLOSTRIDIAL NEUROTOXINS COMPRISING AN ACTIVATING EXOGENOUS PROTEASE CLEAVAGE SITE | IPSEN BIOPHARM LIMITED (GB) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024057031-A1 | CELL-FREE CLOSTRIDIAL NEUROTOXIN ASSAYS | IPSEN BIOPHARM LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| EP-4312964-A1 | CLOSTRIDIAL NEUROTOXINS COMPRISING AN EXOGENOUS ACTIVATION LOOP | Ipsen Biopharm Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313120-A1 | TREATMENT OF PAIN & INFLAMMATORY DISORDERS | Ipsen Biopharm Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| EP-4305050-A2 | MODIFIED CLOSTRIDIAL NEUROTOXINS | Ipsen Biopharm Limited (GB) | 2024-01-17 | — | — | EP | disclosed |
| EP-4297773-A1 | CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS | Ipsen Biopharm Limited (GB) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023209385-A1 | TREATMENT OF LIMB SPASTICITY | IPSEN BIOPHARM LIMITED (GB) | 2023-11-02 | — | — | WO | disclosed |
| WO-1997033913-A1 | CYTOKINE-RECEPTOR EXPRESSED IN TESTIS CELLS | ZYMOGENETICS, INC. (US) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997032984-A1 | DIABETES MELLITUS 37 kD AUTOANTIGEN PROTEIN-TYROSINE PHOSPHATASE | ZYMOGENETICS, INC. (US) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997025424-A1 | OB PROTEIN RECEPTOR AND RELATED COMPOSITIONS AND METHODS | AMGEN INC. (US) | 1997-07-17 | — | — | WO | disclosed |
| EP-0745125-A1 | HEMATOPOIETIC PROTEIN AND MATERIALS AND METHODS FOR MAKING IT | ZymoGenetics, Inc. (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0723456-A1 | METHODS FOR STIMULATING ERYTHROPOIESIS USING THROMBOPOIETIN | THE UNIVERSITY OF WASHINGTON (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996020955-A1 | PURIFIED THROMBOPOIETIN AND METHOD OF MAKING IT | ZYMOGENETICS, INC. (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996017062-A1 | LOW MOLECULAR WEIGHT THROMBOPOIETIN | ZYMOGENETICS, INC. (US) | 1996-06-06 | — | — | WO | disclosed |
| WO-1996017067-A1 | METHOD FOR SECRETING THROMBOPOIETIN POLYPEPTIDES | ZYMOGENETICS, INC. (US) | 1996-06-06 | — | — | WO | disclosed |
| WO-1995021920-A1 | HEMATOPOIETIC PROTEIN AND MATERIALS AND METHODS FOR MAKING IT | ZYMOGENETICS, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995021626-A1 | METHODS FOR STIMULATING ERYTHROPOIESIS USING THROMBOPOIETIN | UNIVERSITY OF WASHINGTON (US) | 1995-08-17 | — | — | WO | disclosed |